PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-0.03%
Cash & equivalents declining -0.03% while Medical - Pharmaceuticals shows -8.55% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-0.03%
Below half the Medical - Pharmaceuticals median of -9.02% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
9.07%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.97%. Jim Chanos might see a serious red flag in ballooning receivables.
3.03%
Inventory growth near Medical - Pharmaceuticals median of 2.84%. Charlie Munger sees standard industry practice. Check for normal demand patterns.
43.68%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
3.40%
Below half the Medical - Pharmaceuticals median of -2.40%. Jim Chanos would question if the company faces working capital strain.
3.45%
PP&E growth below half of Medical - Pharmaceuticals median of -0.44%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-6.22%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-6.22%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-79.83%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-292.06%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
157.47%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.35%
≥ 1.5x the Medical - Pharmaceuticals median of 0.16%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-71.43%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
3.36%
Below half the Medical - Pharmaceuticals median of -0.88%. Jim Chanos might see potential stagnation or distress vs. peers.
6.88%
Payables growth 1.25-1.5x Medical - Pharmaceuticals median of 5.25%. Guy Spier is cautious about potential liquidity tactics or extended terms.
No Data
No Data available this quarter, please select a different quarter.
-44.14%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-84.88%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
78.17%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
5.41%
Below half Medical - Pharmaceuticals median of -4.60%. Joel Greenblatt sees more conservative short-term leverage than peers.
-6.84%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
100.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger extended contract coverage.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
95.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.58%
Above 1.5x Medical - Pharmaceuticals median of -0.56%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
4.73%
Below half Medical - Pharmaceuticals median of -1.47%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.09%
Below half Medical - Pharmaceuticals median of -2.36%. Jim Chanos suspects poor profitability or large dividend drains.
-2.50%
AOCI growth below half of Medical - Pharmaceuticals median 8.60%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.00%
Below half Medical - Pharmaceuticals median of -2.71%. Jim Chanos suspects slower net worth growth or losses vs. peers.
3.36%
Below half Medical - Pharmaceuticals median of -1.02%. Jim Chanos suspects a major slowdown or distress.
108800.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-33.66%
Above 1.5x Medical - Pharmaceuticals median of -1.69%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-22.05%
Below half of Medical - Pharmaceuticals median 4.80%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.